Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies

Blood

Volumn 119, Issue 1, 2012, Pages 180-187

  Gaudio, Eugenio ^a,b   Spizzo, Riccardo ^c   Paduano, Francesco ^b   Luo, Zhenghua ^a   Efanov, Alexey ^a   Palamarchuk, Alexey ^a   Leber, Amanda S ^a   Kaou, Mohamed ^a   Zanesi, Nicola ^a   Bottoni, Arianna ^a   Costinean, Stefan ^a   Rassenti, Laura Z ^d   Nakamura, Tatsuya ^a   Kipps, Thomas J ^d   Aqeilan, Rami I ^a,e   Pekarsky, Yuri ^a   Trapasso, Francesco ^a,b   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CELL PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; T CELL LEUKEMIA 1 PROTEIN; T CELL LYMPHOMA 1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA; LIQUID CHROMATOGRAPHY; LYMPHOMA; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; TANDEM MASS SPECTROMETRY; UBIQUITINATION;

EID: 84862938297     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-374561     Document Type: Article

References (32)

1. Pekarsky Y, Halas C, Isobe M, Russo G, Croce CM. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci U S A. 1999;96(6):2949-2951. (Pubitemid 29148824)
2. Narducci MG, Fiorenza MT, Kang SM, et al. TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc Natl Acad Sci U S A. 2002;99(18):11712-11717. (Pubitemid 34994464)
3. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A. 1994;91(26): 12530-12534.
4. Madani A, Choukroun V, Soulier J, et al. Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood. 1996;87(5):1923-1927.
5. Narducci MG, Virgilio L, Engiles JB, et al. The murine Tcl1 oncogene: embryonic and lymphoid cell expression. Oncogene. 1997;15(8):919-926. (Pubitemid 27399553)
6. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66(24):11590-11593. (Pubitemid 46094168)
7. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002;99(10):6955-6960. (Pubitemid 34526239)
8. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006;103(31):11713-11718. (Pubitemid 44182516)
9. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A. 2000;97(7):3028-3033. (Pubitemid 30183249)
10. Pekarsky Y, Palamarchuk A, Maximov V, et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008;105(50):19643-19648.
11. Hofbauer SW, Pinon JD, Brachtl G, et al. Modifying akt signaling in B-cell chronic lymphocytic leukemia cells. Cancer Res. 2010;70(18):7336-7344.
12. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3(3):155-168. (Pubitemid 37328868)
13. Sherman MH, Kuraishy AL, Deshpande C, et al. AID-induced genotoxic stress promotes B cell differentiation in the germinal center via ATM and LKB1 signaling. Mol Cell. 2010;39(6):873-885.
14. Gabellini C, Antonelli A, Petrinelli P, et al. Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1. Br J Cancer. 2003;89(6):1091-1095. (Pubitemid 37239217)
15. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000;1(3):179-186.
16. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006;13(5):738-747.
17. Jung M, Kondratyev A, Lee SA, Dimtchev A, Dritschilo A. ATM gene product phosphorylates I kappa B-alpha. Cancer Res. 1997;57(1):24-27. (Pubitemid 27020322)
18. Grosjean-Raillard J, Tailler M, Ades L, et al. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 2009;28(8):1099-1109.
19. Wu ZH, Shi Y, Tibbetts RS, Miyamoto S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science. 2006;311(5764):1141-1146.
20. Rosato RR, Kolla SS, Hock SK, et al. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMOrelated pathway. J Biol Chem. 2010;285(13):10064-10077.
21. Hayden MS, Ghosh S. Shared principles in NFkappaB signaling. Cell. 2008;132(3):344-362.
22. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000;6(2):395-407.
23. Narducci MG, Virgilio L, Isobe M, et al. TCL1 oncogene activation in preleukemic T cells from a case of ataxia-telangiectasia. Blood. 1995;86(6):2358-2364.
24. Thick J, Metcalfe JA, Mak YF, et al. Expression of either the TCL1 oncogenes, or transcripts from its homologue MTCP1/c6.1B, in leukemic and nonleukemic T cells from ataxia telangiectasia patients. Oncogene. 1996;12(2):379-386. (Pubitemid 26045206)
25. Dedon PC, JiangZW, Goldberg IH. Neocarzinostatinmediated DNA damage in a model AGT.ACT site: mechanistic studies of thiol-sensitive partitioning of C4 DNA damage products. Biochemistry. 1992;31(7):1917-1927.
26. Tanaka T, Huang X, Halicka HD, et al. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A. 2007;71(9): 648-661. (Pubitemid 47351228)
27. Künstle G, Laine J, Pierron G, et al. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol Cell Biol. 2002;22(5):1513-1525. (Pubitemid 34150787)
28. Shifera AS. Protein-protein interactions involving IKKgamma (NEMO) that promote the activation of NF-kappaB. J Cell Physiol. 2010;223(3):558-561.
29. Thyss R, Virolle V, Imbert V, Peyron JF, Aberdam D, Virolle T. NF-kappaB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. EMBO J. 2005;24(1):128-137. (Pubitemid 40188470)
30. Pekarsky Y, Zanesi N, Aqeilan RI, Croce CM. Animal models for chronic lymphocytic leukemia. J Cell Biochem. 2007;100(5):1109-1118. (Pubitemid 46480394)
31. Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111(1): 328-337.
32. Ropars V, Despouy G, Stern MH, Benichou S, Roumestand C, Arold ST. The TCL1A oncoprotein interacts directly with the NF-KappaB inhibitor IkappaB. PloS One. 2009;4(8):e6567.